Skip Navigation
Skip to contents

JLC : Journal of Liver Cancer



Page Path
HOME > J Liver Cancer > Volume 22(2); 2022 > Article
Notice of Retraction and Replacement
Yoon et al. Hepatocellular Carcinoma in Korea: an Analysis of the 2015 Korean Nationwide Cancer Registry
Jeong-Hoon Lee, MD, PhD
Journal of Liver Cancer 2022;22(2):207-207.
Published online: June 8, 2022

Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea

Copyright © 2022 The Korean Liver Cancer Association

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 1 Citation
This retracted the article "Hepatocellular Carcinoma in Korea: an Analysis of the 2015 Korean Nationwide Cancer Registry" on page 58.
To the Editor: On behalf of our coauthors, we write to report serious errors in our article, “Hepatocellular Carcinoma in Korea: an Analysis of the 2015 Korean National Cancer Registry,” published in the first 2021 issue of Journal of Liver Cancer.1
This article descriptively reports the characteristics of Korean patients who were newly diagnosed with hepatocellular carcinoma (HCC) in 2015 using data from the Korean Primary Liver Cancer Registry (KPLCR). Regrettably, we found critical errors incurred by the misclassification of Barcelona Clinic Liver Cancer (BCLC) tumor stage provided from the KPLCR. Specifically, single nodular HCCs with maximal diameter larger than 5 cm were mistakenly classified as BCLC stage B in the original manuscript, although they should have been classified as BCLC stage A. In addition, survival data were also updated during the correction.
The corrections to address these errors are as follows:
● The proportion of BCLC stage A has increased from 26.3% to 31.5% and that of BCLC stage B has decreased from 7.6% to 12.7% to 7.6% (Table 1) after revising BCLC stage.
● The proportions of each initial treatment modality have been corrected (Figure 1).
● Median overall survival and overall survival rates at years 1, 2, 3, 4, and 5 of respective subgroups were updated (Table 3 and Figure 3).
We hope the medical and scientific community is informed of the results of our reanalysis of the outcomes of our study. We sincerely apologize for these unintentional errors, and considering the extent of the corrections, we have requested that the original article be retracted and replaced. Two additional online supplements containing the original article with the errors highlighted and the corrected article with the corrections highlighted will accompany the replacement article.
  • 1. Yoon JS, Lee HA, Kim HY, et al. Hepatocellular carcinoma in Korea: an analysis of the 2015 Korean Nationwide Cancer Registry. J Liver Cancer 2021;21:58−68.ArticlePubMedPMCPDF

Figure & Data



    Citations to this article as recorded by  
    • Validation of MELD 3.0 scoring system in East Asian patients with cirrhosis awaiting liver transplantation
      Jeong-Ju Yoo, Jong-In Chang, Ji Eun Moon, Dong Hyun Sinn, Sang Gyune Kim, Young Seok Kim
      Liver Transplantation.2023; 29(10): 1029.     CrossRef

    • PubReader PubReader
    • ePub LinkePub Link
    • XML DownloadDownload Citation
      Download Citation
      Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

      • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
      • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
      • Citation for the content below
      Yoon et al. Hepatocellular Carcinoma in Korea: an Analysis of the 2015 Korean Nationwide Cancer Registry
      J Liver Cancer. 2022;22(2):207-207.   Published online June 8, 2022
    • XML DownloadXML Download
    Related articles

    JLC : Journal of Liver Cancer